ReviewAAPS PharmSciTech2015
Colon-targeted oral drug delivery systems: design trends and approaches.
Review in AAPS PharmSciTech, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed.
- Innovative 3D-Printed Devices with Modified Prednisolone Release for Colon-Targeted Drug Delivery Systems.Pharmaceutics · 2026Article
- From triggers to interfaces: polymer-stabilized nano-co-crystals for robust mesalazine delivery in UC.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Delivering the Gut to the Brain: Drug Delivery Strategies for Microbiota-Derived Therapeutics in Depression.Pharmaceutics · 2026Review
- Phospholipid-Prednisolone Conjugates for Targeted IBD Therapy: Structural Design, Synthetic Approaches, Optimization, and Computational Evaluation.Molecules (Basel, Switzerland) · 2026Article
- Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation.Drugs in R&D · 2026Article
- Development of pH-Dependent Magnetically Actuated Millirobot for Colon-Targeted Delivery of Diverse Drug Types.Micromachines · 2026Article
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Delivery Strategies and Clinical Significance of Oral Colon-targeted Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- Rationally Designed Dual Kinase Inhibitors for Management of Obstructive Sleep Apnea-A Computational Study.Biomedicines · 2026Article
- From bench to bowel: translating targeted drug delivery through gastrointestinal barriers.Frontiers in bioengineering and biotechnology · 2026Review
- Microbiome-aware oral drug delivery: excipient-microbiome interactions and nanocarrier design rules for predictable formulation performance.Frontiers in pharmacology · 2026Review
- Microbiota-Sensitive Nanocarriers for the Targeted Delivery of Therapeutic Agents into the Gut: Advanced Treatment Strategy for Inflammatory Bowel Disease.Current pharmaceutical design · 2026Review
- Formulation and Evaluation of Capecitabine-Loaded Microsponges for Colon Targeting.Current drug delivery · 2026Article
- pH-responsive Oral liposomal delivery of hydrogen sulfide donor GYY4137 enables colon-targeted therapy for inflammatory bowel disease.Journal of nanobiotechnology · 2025Article
- Progress and challenges of functionalized bacterial encapsulation: A novel biotechnology for next-generation biotherapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Advances in Intestinal-Targeted Release of Phenolic Compounds.Nutrients · 2025Review
- Oral dosage forms for drug delivery to the colon: an existing gap between research and commercial applications.Journal of materials science. Materials in medicine · 2025Review
- pH-Dependent Drug Delivery Systems for Ulcerative Colitis Treatment.Pharmaceutics · 2025Review
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Advances in Colon-targeted Drug Delivery Systems: Innovative Strategies for Treating Colonic Disorders and Prospects for the Future.Current pharmaceutical biotechnology · 2025Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. In addition, the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions. Drugs such as proteins and peptides that are known to degrade in the extreme gastric pH, if delivered to the colon intact, can be systemically absorbed by colonic mucosa. In order to achieve effective therapeutic outcomes, it is imperative that the designed delivery system specifically targets the drugs into the colon. Several formulation approaches have been explored in the development colon-targeted drug delivery systems. These approaches involve the use of formulation components that interact with one or more aspects of gastrointestinal (GI) physiology, such as the difference in the pH along the GI tract, the presence of colonic microflora, and enzymes, to achieve colon targeting. This article highlights the factors influencing colon-specific drug delivery and colonic bioavailability, and the limitations associated with CDDS. Further, the review provides a systematic discussion of various conventional, as well as relatively newer formulation approaches/technologies currently being utilized for the development of CDDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.